Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

Clinical trial NCT01625234 · COMPLETED

Trial details

NCT number: NCT01625234
Sponsor: Xcovery Holdings, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Advanced Solid Tumors Non-small Cell Lung Cancer

Start date: 2012-06-01
Primary completion: 2020-09-17
Enrollment: 131

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.